Small molecule purine and pseudopurine derivatives: synthesis, cytostatic evaluations and investigation of growth inhibitory effect in non-small cell lung cancer A549

References

• Binétruy B, Heasley L, Bost F, et al. Concise review: regulation of embryonic stem cell lineage commitment by mitogen-activated protein kinases. Stem Cells 2007;25:1090–5.
   PubMed Web of Science ®Google Scholar
• Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci 2004;117:4619–28.
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279–90.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Haluska P, Tolcher AW, et al. First-in-human phase I study of the oral p38 MAPK inhibitor, Ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer. Clin Cancer Res 2016;22:1095–102.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Javle M, Bekaii-Saab TS, et al. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer 2017;116:575–83.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2016;14:249–56.
   Web of Science ®Google Scholar
• Watanabe K, Otsu S, Hirashima Y, et al. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2016;77:1157–64.
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Infante JR, Kim KB, et al. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. BMC Cancer 2017;17:173.
   PubMed Web of Science ®Google Scholar
• Tai WM, Yong WP, Lim C, et al. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Ann Oncol 2016;27:2210–15.
   PubMed Web of Science ®Google Scholar
• Bachegowda L, Morrone K, Winski SL, et al. Pexmetinib: a novel dual inhibitor of Tie2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia. Cancer Res 2016;76:4841–9.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Khoury HJ, Jabbour E, et al. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res 2015;21:985–94.
   PubMed Web of Science ®Google Scholar
• Auffinger P, Hays FA, Westhof E, Ho PS. Halogen bonds in biological molecules. Proc Natl Acad Sci USA 2004;101:16789–94.
   PubMed Web of Science ®Google Scholar
• Lu Y, Shi T, Wang Y, et al. Halogen bonding – a novel interaction for rational drug design? J Med Chem 2009;52:2854–62.
   PubMed Web of Science ®Google Scholar
• Wilcken R, Zimmermann MO, Lange A, et al. Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J Med Chem 2013;56:1363–88.
   PubMed Web of Science ®Google Scholar
• Bradham C, McClay DR. p38 MAPK in development and cancer. Cell Cycle 2006;5:824–8.
   PubMed Web of Science ®Google Scholar
• Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537–49.
   PubMed Web of Science ®Google Scholar
• Iyoda K, Sasaki Y, Horimoto M, et al. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer 2003;97:3017–26.
   PubMed Web of Science ®Google Scholar
• Bistrović A, Krstulović L, Harej A, et al. Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer. Eur J Med Chem 2017. pii: S0223-5234(17)30863-2. doi: 10.1016/j.ejmech.2017.10.061. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Yan R, Sander K, Galante E, et al. A one-pot three-component radiochemical reaction for rapid assembly of 125I-labeled molecular probes. J Am Chem Soc 2013;135:703–9.
   PubMed Web of Science ®Google Scholar
• Chittepu P, Sirivolu VR, Seela F. Nucleosides and oligonucleotides containing 1,2,3-triazole residues with nucleobase tethers: synthesis via the azide-alkyne ‘click’ reaction. Bioorg Med Chem 2008;16:8427–39.
   PubMed Web of Science ®Google Scholar
• Maračić S, Kraljević TG, Paljetak HČ, et al. 1,2,3-Triazole pharmacophore-based benzofused nitrogen/sulfur heterocycles with potential anti-Moraxella catarrhalis activity. Bioorg Med Chem 2015;23:7448–63.
   PubMed Web of Science ®Google Scholar
• Dürüst Y, Sağırlı A, Kariuki BM, Knight DW. [1,3]-Dipolar cycloaddition of N-aryl sydnones to benzothiophene 1,1-dioxide, 1-cyclopropylprop-2-yn-1-ol and 1-(prop-2-ynyl)-1H-indole. Tetrahedron 2014;70:6012–19.
   Web of Science ®Google Scholar
• Duan YC, Ma YC, Zhang E, et al. Design and synthesis of novel 1,2,3-triazole-dithiocarbamate hybrids as potential anticancer agents. Eur J Med Chem 2013;62:11–19.
   PubMed Web of Science ®Google Scholar
• Gazivoda T, Raić-Malić S, Krištafor V, et al. Synthesis, cytostatic and anti-HIV evaluations of the new unsaturated acyclic C-5 pyrimidine nucleoside analogues. Bioorg Med Chem 2008;16:5624–34.
   PubMed Web of Science ®Google Scholar
• Filimonov DA, Poroikov VV. Probabilistic approaches in activity prediction. In: Varnek A, Tropsha A, eds. Chemoinformatics approaches to virtual screening. Cambridge, UK: RSC Publishing, 2008:182–216.
   Google Scholar
• RSC PDB. Available from: http://www.rcsb.org/pdb/, 2017 [last accessed 31 Mar 2017].
   Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235–42.
   PubMed Web of Science ®Google Scholar
• Chen X, Lin Y, Gilson MK. The binding database: overview and user's guide. Biopolymers 2001;61:127–41.
   PubMed Web of Science ®Google Scholar
• Torch, version 10.4.1., Cresset, Litlington, Cambridgeshire, UK. Available from: http://www.cresset-group.com/torch/ [last accessed 1 Sep 2017].
   Google Scholar
• Friesner RA, Murphy RB, Repasky MP, et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein − ligand complexes. J Med Chem 2006;49:6177–96.
   PubMed Web of Science ®Google Scholar
• Halgren TA, Murphy RB, Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004;47:1750–9.
   PubMed Web of Science ®Google Scholar
• Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739–49.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2017-1: MacroModel, Schrödinger, New York, NY: LLC, 2017.
   Google Scholar
• Li J, Abel R, Zhu K, et al. The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. Proteins Struct Funct Bioinformatics 2011;79:2794–812.
   PubMed Web of Science ®Google Scholar
• Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 1996;118:11225–36.
   Web of Science ®Google Scholar
• Shivakumar D, Williams J, Wu Y, et al. Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput 2010;6:1509–19.
   PubMed Web of Science ®Google Scholar
• Kraljević TG, Harej A, Sedić M, et al. Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole–coumarin hybrids. Eur J Med Chem 2016;124:794–808.
   PubMed Web of Science ®Google Scholar
• Gregorić T, Sedić M, Grbčić P, et al. Novel pyrimidine-2,4-dione–1,2,3-triazole and furo[2,3-d]pyrimidine-2-one–1,2,3-triazole hybrids as potential anti-cancer agents: synthesis, computational and X-ray analysis and biological evaluation. Eur J Med Chem 2017;125:1247–67.
   PubMed Web of Science ®Google Scholar
• He XT, Hannocks MJ, Hampson I, Brunner G. GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy. Clin Exp Metastasis 2002;19:291–9.
   PubMed Web of Science ®Google Scholar
• Brunner G, Zalkow L, Burgess E, et al. Inhibition of glycosylphosphatidylinositol (GPI) phospholipase D by suramin-like compounds. Anticancer Res 1996;16:2513–16.
   PubMed Web of Science ®Google Scholar
• Wang P, Song L, Ge H, et al. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. Oncotargets Ther 2014;7:1761–8.
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim ES, Liu D, et al. Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. Oncotarget 2015;6:16746–56.
   PubMed Web of Science ®Google Scholar
• Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999;401:86–90.
   PubMed Web of Science ®Google Scholar
• Zhao D, Bakirtzi K, Zhan Y, et al. Insulin-like growth factor-1 receptor transactivation modulates the inflammatory and proliferative responses of neurotensin in human colonic epithelial cells. J Biol Chem 2011;286:6092–9.
   PubMed Web of Science ®Google Scholar
• Greenberg AK, Basu S, Hu J, et al. Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol 2002;26:558–64.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Yokote K, Tamura K, et al. Platelet-derived growth factor activates p38 mitogen-activated protein kinase through a Ras-dependent pathway that is important for actin reorganization and cell migration. J Biol Chem 1999;274:13954–60.
   PubMed Web of Science ®Google Scholar
• Cosaceanu D, Budiu RA, Carapancea M, et al. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 2007;26:2423–34.
   PubMed Web of Science ®Google Scholar
• Greenidge PA, Kramer C, Mozziconacci JC, Wolf RM. MM/GBSA binding energy prediction on the PDBbind data set: successes, failures, and directions for further improvement. J Chem Inf Model 2012;53:201–9.
   PubMed Web of Science ®Google Scholar